Until now, most Medicare beneficiaries who wanted Wegovy or Zepbound had exactly one option: pay full price. At roughly $1,350 a month for Wegovy and a similar sticker for Zepbound, according to GoodRx pharmacy pricing data, that meant the vast majority of seniors on fixed incomes simply went without.
That changes on July 1, 2026. A new federal program called the Medicare GLP-1 Bridge will cap what beneficiaries pay for select GLP-1 weight-loss medications at $50 per month through December 31, 2027. The 18-month initiative, announced by the Centers for Medicare and Medicaid Services (CMS), is designed as a stopgap: it gives eligible seniors immediate access to drugs with strong clinical evidence behind them while Congress and CMS work through the harder question of whether Medicare should cover anti-obesity medications permanently.
The math is stark. Under the Bridge, a senior’s annual cost drops from more than $16,000 to $600. For millions of older Americans living on Social Security and modest savings, that gap is the difference between filling a prescription and skipping it entirely.
Which drugs are covered and who qualifies
The Bridge covers three products, all listed on the official CMS announcement:
- Wegovy (semaglutide injection and tablets), Novo Nordisk’s flagship obesity treatment
- Foundayo, Novo Nordisk’s oral semaglutide formulation approved specifically for chronic weight management. This is a different product from Ozempic, which is approved for type 2 diabetes and is not included in the Bridge.
- Zepbound (tirzepatide), Eli Lilly’s dual-action GLP-1/GIP receptor agonist, but only in its KwikPen delivery device. Patients prescribed Zepbound in a different device format do not qualify under the current terms.
To be eligible, a beneficiary must have a body mass index or clinical diagnosis that meets obesity-related thresholds set by CMS, and their prescriber must submit a prior authorization. Enrollees must also be in a Medicare Part D plan or a Medicare Advantage plan that includes drug coverage. CMS absorbs the cost difference between the $50 copay and the drug’s negotiated price during the Bridge period.
Beneficiaries who are already receiving Wegovy, Zepbound, or Foundayo through their Part D plan should check with their plan and prescriber about whether they will transition into the Bridge automatically or need to submit a new prior authorization. CMS has not published specific guidance on this point as of June 2026, so current users should not assume auto-enrollment.
One important note: the Bridge does not appear to cover compounded versions of semaglutide or tirzepatide, which some seniors have turned to as lower-cost alternatives. Beneficiaries using compounded GLP-1 medications should confirm with their prescriber whether switching to a brand-name product under the Bridge makes clinical and financial sense.
CMS has not yet published projected enrollment numbers or detailed how quickly prior authorization decisions will be returned. That gap leaves the program’s practical reach uncertain in its early weeks. Beneficiaries who want to verify their plan status or compare coverage options can do so through Medicare.gov.
Why the price gap has kept these drugs out of reach
GLP-1 receptor agonists have become some of the most talked-about medications in a generation, and the clinical data backs up the attention. Novo Nordisk’s STEP trial program showed that semaglutide produced average sustained weight loss of about 15% of body weight. Eli Lilly’s SURMOUNT-1 trial found that tirzepatide achieved even greater results, with participants losing an average of roughly 22.5% of body weight over 72 weeks. Both trial programs also documented cardiovascular and metabolic benefits beyond weight reduction alone.
Yet list prices above $1,000 a month have made these drugs functionally unavailable to most Medicare enrollees. Part D plans have been slow to add robust obesity drug coverage, and without it, seniors bear nearly the entire cost. The Obesity Action Coalition, a national patient advocacy organization, has repeatedly identified cost as the single largest barrier preventing older adults from accessing GLP-1 therapies that clinical evidence supports.
The Bridge also arrives alongside the Inflation Reduction Act’s $2,000 annual out-of-pocket cap on Part D spending, which took effect in 2025. How the two provisions interact matters. Under the Bridge structure, the $50 monthly cost is the beneficiary’s share, and CMS materials indicate the program operates within the Part D framework. But whether those $50 copays count toward the $2,000 annual cap, and what happens if a patient hits that cap mid-year, are details CMS has not fully clarified in public documents as of June 2026. Beneficiaries approaching the cap should ask their Part D plan directly.
What CMS has not disclosed
Several important pieces of the program remain opaque, and they matter for anyone trying to assess whether the Bridge will last or expand.
First, CMS has not released cost-savings modeling. Obesity drives enormous downstream spending on hospitalizations, type 2 diabetes management, cardiovascular events, and joint replacements. If the Bridge reduces those costs enough to offset the upfront drug spending, the fiscal case for extending the program strengthens considerably. Without that analysis, the sustainability argument is incomplete.
Second, the agency has not disclosed the rebate or discount arrangements it negotiated with Novo Nordisk and Eli Lilly. The $50 is what patients pay at the pharmacy counter, but the true net cost to Medicare depends on confidential manufacturer agreements that do not appear in any public-facing materials.
Third, prior authorization specifics are thin. The program page outlines clinical eligibility thresholds but does not describe how disputes will be handled or whether CMS will track and publish denial rates. Until the agency issues more targeted guidance, patients and prescribers should expect that standard Medicare Part D appeals rules apply.
The 18-month clock and what happens in January 2028
The Bridge’s temporary design is its most consequential feature, and its biggest risk.
Patients who begin GLP-1 therapy in mid-2026 could face a sharp cost cliff on January 1, 2028, when the program expires. Clinical evidence is consistent on this point: weight-loss medications require ongoing use to maintain results. The STEP 1 trial extension data showed that participants who discontinued semaglutide regained roughly two-thirds of lost weight within a year. That means the Bridge creates a foreseeable discontinuity for patients and the physicians managing their care.
Whether the program gets extended depends on several moving parts. Congress has considered but not passed the Treat and Reduce Obesity Act, which would make anti-obesity medications a permanent Medicare benefit. CMS could also use its administrative authority to extend or modify the Bridge, but the agency has not signaled its intentions beyond the current December 2027 end date.
Health policy groups, including the KFF (formerly the Kaiser Family Foundation), have flagged temporary subsidies for chronic conditions as structurally risky: they create reliance on a benefit that may vanish, leaving patients and providers scrambling. That concern is especially acute here, where abrupt discontinuation carries documented clinical consequences.
What seniors should do before July 1
Beneficiaries who think they may qualify should not wait for the program to launch. Prior authorization takes time, and securing approval before July 1 could mean filling that first $50 prescription on day one. Here is a practical checklist:
- Talk to your prescriber now. Ask whether you meet the clinical criteria and whether Wegovy, Zepbound, or Foundayo is appropriate for you.
- Confirm your Part D or Medicare Advantage drug coverage. The Bridge requires enrollment in a qualifying plan. Check your status at Medicare.gov.
- Ask about prior authorization timelines. Your prescriber’s office can submit the request, but processing times vary by plan.
- If you already take a covered GLP-1 through Part D, contact your plan to ask whether you will be moved into the Bridge program automatically or need a separate prior authorization.
- Understand the 18-month window. The Bridge runs through December 31, 2027. Discuss with your doctor what the plan looks like if the program is not extended.
For seniors who have been priced out of GLP-1 medications for years, the Bridge is the most significant access shift Medicare has made on obesity treatment. Whether it becomes a permanent change or a brief window depends on decisions that have not been made yet. The 18 months start July 1.
Warren Cohen is a finance writer based in Phoenix, Arizona, covering personal finance topics including credit, banking, and beginner investing. He earned his degree in business administration from Arizona State University and began his career working in consumer finance, where he gained direct experience with lending and credit systems. He now writes for personal finance websites and fintech platforms, focusing on clear, practical content that helps readers make informed financial decisions.
